Amivantamab

Therapeutic indications

Amivantamab is indicated for:

Advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR)

Irrespective of gender only Adults (18 years old or older)

Amivantamab as monotherapy is indicated for treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based therapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1050-1400 mg once every 1 or 2 weeks